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OBJECTIVES: Increased arterial stiffness is an important determinant of the risk of cardiovascular disease. Lipid
profile impairment, especially hypercholesterolemia, is associated with stiffer blood vessels. Thus, the aim of this
study was to determine which of the five circulating lipid components (high-density lipoprotein cholesterol
(HDL-C), non-high-density lipoprotein cholesterol (non-HDL-C), low-density lipoprotein cholesterol (LDL), total
cholesterol (TC) and triglycerides) is the best predictor of increased arterial stiffness in an urban Brazilian
population.
METHODS: A random sample of 1,662 individuals from the general population of Vitoria, Brazil (25-64 years),
was selected, and lipid components were measured using standard methods. Pulse wave velocity was mea-
sured using a non-invasive automatic device, and increased arterial stiffness was defined as a pulse wave
velocity X10 m/s.
RESULTS: In men, only total cholesterol (OR=1.59; CI=1.02 to 2.48, p=0.04) was associated with the risk of
increased arterial stiffness. In women, HDL-C (OR=1.99; CI=1.18 to 3.35, p=0.01) and non-HDL-C (OR=1.61;
CI=1.01 to 2.56, p=0.04) were good predictors of the risk of increased arterial stiffness. However, these
associations were only found in postmenopausal women (OR=2.06; CI=1.00 to 4.26, p=0.05 for HDL-C and
OR=1.83; CI=1.01 to 3.33, p=0.04 for non-HDL-C).
CONCLUSION: Our findings indicate that both HDL-C and non-HDL-C are good predictors of the risk of increased
arterial stiffness in postmenopausal women in an urban Brazilian population and may be useful tools for
assessing the risk of arterial stiffness.
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’ INTRODUCTION
Increased arterial stiffness is an important determinant of
cardiovascular disease (CVD) risk (1). Several epidemiological
studies have reported that increased arterial stiffness predicts
morbidity and mortality independently of other cardiovascu-
lar risk factors (2, 3). Stiffness of the large arteries, which is mea-
sured using carotid-femoral pulse wave velocity (PWV) - the
gold standard method for assessing this parameter - has been
associated with measures of subclinical atherosclerosis and
CVD (4). Furthermore, clinical studies have shown that
arterial stiffness increases with age or in several pathological
processes, such as hypertension, metabolic syndrome, chronic
renal disease, hypercholesterolemia, and menopause (5-10).
Changes in the lipid profile, especially hypercholesterole-
mia, may contribute to changes in vascular stiffness (9). Several
studies have recently investigated the association between
arterial stiffness and lipid profile-related parameters, such as
non-high-density lipoprotein cholesterol (non-HDL-C), low
density lipoprotein cholesterol (LDL-C) and the non-HDL/
HDL-C ratio (11-13). However, the results reported to date
are far from conclusive because the results of only 10% of the
studies on this subject suggested that a positive association
exists between these variables, while most of the studies
failed to find such a correlation between the variables (14). In
addition, the results of the studies showing that any serumDOI: 10.6061/clinics/2017(02)07
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lipid parameter is a superior predictor of the risk of increased
arterial stiffness compared to other lipid profile parameters
are still inconclusive.
Based on this scenario and on the clinical applicability of
lipid profile and arterial stiffness measurements, the aim of
this study was to determine which of the five measurements
recommended to assess cardiovascular risk (HDL-C, non-
HDL-C, LDL-C, total cholesterol (TC) and triglycerides) is
the best predictor of the risk of increased arterial stiffness in
an urban Brazilian population. Moreover, we also assessed
the possible influence of menopause on PWV values.
’ METHODS
Subjects
A study of the risk factors for CVDs was performed in the
urban population of Vitoria, Brazil, using the WHO-MONICA
Project guidelines (15). The study design was based on a cross-
sectional research methodology and was developed by sur-
veying and analyzing socioeconomic and health data in a
probabilistic sample of residents from the municipality of
Vitoria, Espírito Santo, Brazil. The objective of the sampling
plan was to ensure that the research was socioeconomically,
geographically, and demographically representative of the
residents of this municipality. Residents of the city of Vitoria
ranging from 25-64 years of age were included in the study.
According to the census conducted by the IBGE Foundation in
1996, the resident population of Vitoria included 265,874 inha-
bitants. Sampling was performed in four stages as follows: by
district, by IBGE census sector, by drawing lots to choose
homes, and by birthday to choose an individual from each
home. The survey was conducted with only one resident
(chosen according to the nearest birthday after homes were
randomly selected) from the selected home who was within
the aforementioned age range of the study. The draw was
conducted using a randomization mechanism. A total of 2,268
residential homes were selected and visited. The research
purposes were explained to the individual selected in his/her
home, and he/she was invited to participate in the study after
providing his/her written consent. The selected individuals
were asked to visit the Cardiovascular Investigation Clinic of
the University Hospital within 2 weeks after selection so that
their tests could be performed. Among the total sample, 1,662
individuals (761 men and 901women) visited the clinic. This
study was approved by the Ethics Committee for Research on
Human Subjects of the Espírito Santo Federal University and
the National Ethics Committee for Human Research (CONEP
Register Number 4599).
Anthropometrical Investigations
Anthropometric parameters were measured according to a
standard protocol (16). Body weight was measured to the
nearest 0.1 kg on a calibrated scale, and height was measured
to the nearest 0.5 cm using a wall-mounted stadiometer. Waist
circumference was measured at the mean point between the
lowest rib margin and the iliac crest at the maximum point of
normal expiration while the subject stood (17). Body mass
index (BMI) was calculated as body weight (kg) divided by
height squared (m2).
Biochemical Measurements
Blood glucose levels, triglyceride levels and lipoprotein
fractions were assayed with standard techniques using 12-h
fasting blood samples (18). Non-HDL-C was calculated by
subtracting HDL-C from TC. The following biochemical
parameter results were categorized as abnormal: a TC level
X240 mg/dL, a triglyceride level X200 mg/dL, an LDL-C
level X160 mg/dL, an HDL-C level p39 mg/dL, and a
non-HDL-C level X190 mg/dL (19). Diabetes mellitus was
diagnosed based on the presence of a fasting glucose level
X126 mg/dL and/or antidiabetic drug use (20), and hyper-
lipidemia was defined as a TC levelX240 mg/dL, an LDL-C
level X160 mg/dL, and/or hypolipidemic drug use (21).
PWV Determination
Carotid-femoral PWV was measured with the patient in
the supine position with an automatic and validated device
(Complior; Artech Medical, France) operated by an experi-
enced observer who was blinded to the patients’ clinical
characteristics. Briefly, common carotid artery and femoral
artery pressure waveforms were recorded non-invasively
using pulse-sensitive transducers. PWV was measured within
a period ranging from 10–15 seconds, and carotid-femoral
distance was used to assess PWV. The distance between the
recording sites (D) was measured, and PWV was calculated
automatically as PWV=D/t, where (t) is the pulse transit time.
The measurements were repeated over 10 different cardiac
cycles. According to recent recommendations, increased
arterial stiffness was defined as a PWVX10 m/s (22). The
validation of this automatic method and its reproducibility
have been described previously (23).
Assessment of Menopausal Status
Information regarding the menopausal statuses of the
women in the present study was evaluated using a question-
naire that was completed by each participant in an interview
during the clinic visit. The questionnaire was based on the
WHO-MONICA epidemiological instrument (15) and was
administered and filled out by research assistants who were
specially trained for the task.
Statistical Analysis
Categorical variables are presented as percentages, whereas
continuous variables are presented as the mean±standard
deviation. Binary logistic regression analysis was performed to
evaluate the associations between lipid profile parameters
(HDL-C, non-HDL-C, LDL-C, TC and triglycerides) and
arterial stiffness, allowing for covariates (mean blood pressure
and age). The data are presented as odds ratios (ORs) and 95%
confidence intervals (CIs). The same analysis was also perfor-
med second time only for women and was stratified by meno-
pausal status (premenopausal and postmenopausal women).
Statistical analyses were conducted using IBM SPSS Statistics
for Windows, Version 19.0. Armonk, NY, USA, with the level
of significance set at 5%.
’ RESULTS
The results are presented such that they emphasize the
relationship between lipid components and increased arterial
stiffness in women because some lipid components were
strongly associated with increased arterial stiffness in this
group, especially in postmenopausal women.
Stratified by sex, the demographic data related to age,
BMI, waist circumference, fasting glucose, PWV, TC, HDL-C,
LDL-C, non-HDL-C, very-low-density lipoprotein cholesterol
(VLDL), triglycerides and the presences of diabetes, smoking,
hypertension, hyperlipidemia and increased arterial stiffness
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for the entire sample are summarized in Table 1. The demo-
graphic data stratified by the menopausal statuses of the
women are presented in Table 2.
Association Between Lipid Profile Parameters and
Increased Arterial Stiffness
In men, only TC (OR=1.59; CI=1.02 to 2.48, p=0.04) was
significantly associated with increased arterial stiffness (Table 3).
However, in women, both HDL-C (OR=1.99; CI=1.18 to 3.35,
p=0.01) and non-HDL-C (OR=1.61; CI=1.01 to 2.56, p=0.04) were
known to be good predictors of the risk of increased arterial
stiffness (Table 3). When stratified by menopausal status, the
same analysis showed that this association was significant only
for postmenopausal women (OR=2.06; CI=1.00 to 4.26, p=0.05
for HDL-C and OR=1.83; CI=1.01 to 3.33, p=0.04 for non-
HDL-C) (Table 4). Accordingly, none of the lipid profile para-
meters were significantly associated with increased arterial
stiffness in premenopausal women.
’ DISCUSSION
The main finding of our study was that there were positive
associations between HDL-C and non-HDL-C and increased
arterial stiffness in postmenopausal women. These results
were not replicated in men and premenopausal women. In
addition, postmenopausal women displayed higher LDL-C,
triglyceride, TC, non-HDL-C and PWV levels than preme-
nopausal women.
In the last few decades, researchers have noted an asso-
ciation between aging and dyslipidemia. In men, lipid
profiles become more unfavorable because of the decreases
in testosterone levels that occur with age. Similarly, in women,
menopause is associated with a more atherogenic lipid profile
than premenopausal status (24). Studies have shown associa-
tions between the onset of menopause and the increased
prevalence of cardiovascular risk factors. The lack of estrogen
facilitates the development of diabetes, hypertension, obesity
and dyslipidemia (25). In our study, we also showed that a
decrease in estrogen predisposes individuals to developing
increased arterial stiffness, which is an additional and inde-
pendent risk factor for CVD. Experimental studies have
demonstrated that estrogen is highly effective in preventing
LDL-C and VLDL-C oxidation (26). In addition, endogenous
estrogen production in premenopausal women is associa-
ted with low LDL-C levels and high HDL-C levels (27).
Mogarekar and Kulkarni (28) showed that postmenopausal
women had significantly increased serum triglycerides and
small dense LDL-C levels, as well as significantly decreased
HDL-C and paraoxonase-1 levels, compared to premenopau-
sal women. These findings may explain the low prevalence
of CVD in premenopausal women. In the present study,
Table 2 - Clinical characteristics of the women stratified by menopause status.
Characteristics Premenopausal Women Postmenopausal Women p-value
Age, y 40.2±8.9 54.8±6.7 o0.001
BMI, kg/m2 26.2±5.6 27.4±5.1 0.002
Waist circumference, cm 81.7±12.5 87.3±12.6 o0.001
Fasting glucose, mg/dL 99.4±22.5 114.1±49.6 o0.001
PWV, m/s 7.0±1.9 8.3±2.2 o0.001
CT, mg/dL 203.8±40.5 239.9±45.2 o0.001
LDL-C, mg/dL 135.2±36.6 161.6±41.2 o0.001
HDL-C, mg/dL 47.9±12.5 48.6±10.9 0.39
Non-HDL-C, mg/dL 156.5±42.5 191.2±50.3 o0.001
Triglycerides, mg/dL 106.6±78.1 145.0±96.9 o0.001
Smoking (%) 19.8 18.6 0.42
Increased arterial stiffness (%) 6.6 24.4 o0.001
Diabetes (%) 5.1 14.7 o0.001
Hypertension (%) 28.1 60.7 o0.001
Hyperlipidemia (%) 18.4 42.7 o0.001
Continuous data are expressed as the mean±standard deviation.
BMI, body mass index; PWV, pulse-wave velocity; TC, total cholesterol; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein
cholesterol; Non-HDL-C, non-high-density lipoprotein cholesterol.
Hypertension: mean systolic blood pressure X140 mmHg, mean diastolic blood pressure X90 mmHg and/or anti-hypertensive drug use.
Diabetes: fasting glucose X126 mg/dL and/or hypoglycemic drug use.
Increased arterial stiffness: pulse wave velocity (PWV)X10 m/s.
Hyperlipidemia: TCX240 mg/dL, LDL-CX160 mg/dL, and/or hypolipidemic drug use.
Table 1 - Characteristics of the subjects in the sample.
Characteristics Men Women
N 761 901
Age, years 44.7±10.9 44.8±10.7
BMI, kg/m2 25.9±4.0 26.6±5.5
Waist circumference, cm 89.1±10.9 83.6±12.9
Fasting glucose, mg/dL 105.3±28.2 104.0±33.9
Smoking (%) 25.6 19.5
Hypertension (%) 47.6 38.1
Diabetes (%) 7.1 8.2
Hyperlipidemia (%) 26.9 25.9
Increased arterial stiffness (%) 19.3 12.1
PWV, m/s 7.9±2.3 7.4±2.1
TC, mg/dL 213.3±50.8 215.2±44.9
HDL-C, mg/dL 42.3±12.3 48.0±11.9
LDL-C, mg/dL 140.4±39.4 143.6±39.8
Non-HDL-C, mg/dL 171.6±55.2 167.5±47.6
VLDL-C, mg/dL 29.2±24.7 22.8±15.1
Triglycerides, mg/dL 163.5±175.9 118.4±85.8
BMI, body mass index; PWV, pulse-wave velocity; TC, total cholesterol;
HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density
lipoprotein cholesterol; Non-HDL-C, non-high-density lipoprotein
cholesterol; VLDL-C, very-low-density lipoprotein cholesterol.
Hypertension: mean systolic blood pressure X140 mmHg, mean diastolic
blood pressure X90 mmHg and/or anti-hypertensive drug use.
Diabetes: fasting glucose X126 mg/dL and/or hypoglycemic drug use.
Increased arterial stiffness: pulse-wave velocity (PWV) X10 m/s.
Hyperlipidemia: TCX240 mg/dL, LDL-CX160 mg/dL, and/or hypolipidemic
drug use.
Continuous data are expressed as the mean±standard deviation.
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postmenopausal women displayed worse lipid profiles and
higher prevalences of hypertension, diabetes and increased
arterial stiffness than premenopausal women. Thus, it is
possible that the development of cardiometabolic disorders
can be partially explained by deficient or absent estrogen
production.
Increased central arterial stiffness is an important determi-
nant of CVD risk (1), and previous studies have demonstrated
that an association exists between hypercholesterolemia and
stiffer blood vessels (9). In our study, the lipid profile was
associated with increased arterial stiffness in postmenopausal
women; i.e., high HDL-C and non-HDL-C levels were asso-
ciated with increased arterial stiffness. As previously described,
estrogen plays a key role in lipid metabolism and cardio-
vascular risk among women (25, 27). Thus, our data suggest
that increased arterial stiffness in postmenopausal women
may result from the lipid profile parameter worsening asso-
ciated with decreased estrogen levels.
Several studies have focused on the relationship between
the lipid profile and arterial stiffness. Holewijn et al. (11)
studied 1517 individuals aged 50-70 years and showed that
non-HDL-C was superior to LDL-C with respect to identify-
ing individuals with compromised cardiovascular pheno-
types, including individuals with high arterial stiffness, from
the general population, results that partially corroborated
ours. In contrast, Zhao et al. (13) studied a middle-aged and
elderly Chinese population and showed that the non-HDL-c/
HDL-C ratio was superior to traditional lipid variables with
respect to estimating arterial stiffness risk. Finally, Wang
et al. (12) studied 2375 individuals aged 40-96 years and
showed that only LDL-C and HDL-C were independently
associated with aortic stiffness. However, that study did not
evaluate the role of non-HDL-C with respect to the risk of
aortic stiffness. As stated above, we were limited with
respect to our ability to compare our results with those of
previous studies in the literature due to the variety of
methods used to assess arterial stiffness in those studies and
the differences between those studies and ours with regard
to the statistical methods used for analyses.
In the present study, non-HDL-C was a good predictor of
the risk of increased arterial stiffness in postmenopausal
women belonging to an urban Brazilian population. Our
data were partially corroborated by the results of several
population studies demonstrating that non-HDL-C is a better
marker of CVD risk than LDL-C alone (29, 30). Another
important finding of our study is that the association
between the lipid profile and increased arterial stiffness
was significant only in postmenopausal women, a find-
ing suggestive of the impact of estrogen on lipid metabolism
(26, 27).
Our study had some limitations. First, we did not obtain
measurements of follicle stimulating hormone (FSH) levels;
therefore, we were unable to make a laboratory diagnosis
of menopause. Second, this study was a cross-sectional
analysis. Therefore, a causal relationship between increased
arterial stiffness and poor lipid profiles could not be
established. Third, in our study, some women were treated
with postmenopausal hormone replacement therapy. Fourth,
hypolipidemic therapy can decrease arterial stiffness (31),
and some participants enrolled in the our study use lipid-
lowering drugs, which may have slightly influenced our
findings.
Table 3 - Analysis of increased arterial stiffness according to the lipid profiles of the sample.
Variables OR (95% CI), p-value
Men Women
TC (X240 versus p239 mg/dL) 1.59 (1.02 to 2.48), 0.04 1.37 (0.86 to 2.18), 0.19
Triglycerides (X200 versus p199 mg/dL) 1.54 (0.97 to 2.46), 0.07 1.67 (0.95 to 2.92), 0.07
HDL-C (p39 versus X40 mg/dL) 0.98 (0.64 to 1.53), 0.94 1.99 (1.18 to 3.35), 0.01
LDL-C (X160 versus p159 mg/dL) 1.10 (0.69 to 1.74), 0.70 1.15 (0.71 to 1.87), 0.56
Non-HDL-C (X190 versus p189 mg/dL) 1.34 (0.87 to 2.06), 0.19 1.61 (1.01 to 2.56), 0.04
TC, total cholesterol; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; Non-HDL-C, non-high-density lipoprotein
cholesterol; PWV, pulse wave velocity.
Increased arterial stiffness = PWVX10 m/s.
All analyses were adjusted for mean blood pressure and age.
p-values in boldface are significant.
OR, odds ratio; 95%CI, 95% confidence interval.
Table 4 - Analysis of increased arterial stiffness according to the lipid profiles of the women stratified by menopause status.
Variables OR (95% CI), p-value
Premenopausal Women Postmenopausal Women
TC (X 240 versus p239 mg/dL) 1.28 (0.58 to 2.79), 0.54 1.37 (0.76 to 2.46), 0.30
Triglycerides (X 200 versus p199 mg/dL) 1.91 (0.76 to 4.80), 0.17 1.64 (0.81 to 3.31), 0.17
HDL-C (p39 versus X40 mg/dL) 1.94 (0.89 to 4.23), 0.09 2.06 (1.00 to 4.26), 0.05
LDL-C (X160 versus p159 mg/dL) 1.23 (0.56 to 2.69), 0.61 1.01 (0.55 to 1.87), 0.98
Non-HDL-C (X190 versus p189 mg/dL) 1.13 (0.52 to 2.47), 0.35 1.83 (1.01 to 3.33), 0.04
TC, total cholesterol; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; Non-HDL-C, non-high-density lipoprotein
cholesterol; PWV, pulse wave velocity.
Increased arterial stiffness = PWVX10 m/s.
All analyses were adjusted for mean blood pressure and age.
p-values in boldface are significant.
OR, odds ratio; 95%CI, 95% confidence interval.
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In summary, this study showed that non-HDL-C may be a
good predictor of the risk of increased arterial stiffness in
postmenopausal women. Thus, we surmise that non-HDL-C
may a useful tool for the assessing the risk of arterial stiffness
during the postmenopausal period.
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